Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold...

  • Tuesday, September 11, 2012, 2:06 PM ET
    ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold on the back of the FDA's rejection of its Lymphoseek application and lack any of visibility on the FDA's review process going forward. The firm also slashes its price target to $2.50 from $7.
Track new comments on this story

This news story has 1 comment:

  •  
    Well then, that was a slam dunk ThinkEquity.

    Regards.
    11 Sep 2012, 02:08 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »